Literature DB >> 17122866

Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy.

K Tokita, K Maki, J Tadokoro, Y Nakamura, Y Arai, K Sasaki, M Eguchi-Ishimae, M Eguchi, K Mitani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17122866     DOI： 10.1038/sj.leu.2404397

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Authors:  Chan Y Cheah; Kate Burbury; Jane F Apperley; Francoise Huguet; Vincenzo Pitini; Martine Gardembas; David M Ross; Donna Forrest; Philippe Genet; Philippe Rousselot; Nigel Patton; Graeme Smith; Cynthia E Dunbar; Sawa Ito; Ricardo C T Aguiar; Olatoyosi Odenike; Alla Gimelfarb; Nicholas C P Cross; John F Seymour
Journal:  Blood       Date:  2014-03-31       Impact factor: 22.113

2.  Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.

Authors:  Yoshimitsu Shimomura; Hayato Maruoka; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2016-12-20       Impact factor: 2.490

3.  T cell acute lymphoblastic lymphoma complicated with myeloid sarcoma in an adult: A case report.

Authors:  Ying Wang; Shupeng Wen; Zhiyun Niu; Lina Xing; Fuxu Wang; Xuejun Zhang
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

Review 4.  PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Authors:  Mirela Andrei; Andrei Bandarchuk; Cherif Abdelmalek; Ajay Kundra; Vladimir Gotlieb; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2017-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.